Patient characteristics
Patient no.* . | Patient age, y . | HCT date . | Allele mismatch . | Antigen mismatch . | CCI score . | No. of prior regimens . | Autologous HCT failed (planned) . | Months from diagnosis to HCT . | Disease status at HCT† . | Disease burden‡ . | Marrow . | Flow cytometry . | Beta2 microglobulin, μg . | LDH . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | 3/7/00 | NMM | NMM | 0 | 2 | 0 | 7.4 | CR1 | minimal | negative | negative | 1.5 | 187 |
| 2 | 52 | 4/29/00 | NMM | NMM | 0 | 2 | 0 | 12.1 | refractory | moderate | positive | negative | ND | ND |
| 3 | 52 | 5/2/00 | NMM | NMM | 0 | 2 | (1) | 4.6 | CR1 | minimal | negative | negative | 1.6 | 215 |
| 4 | 59 | 6/28/00 | NMM | NMM | 4 | 5 | 1 | 20.7 | PR | minimal | negative | negative | 5.6 | 255 |
| 5 | 39 | 11/17/00 | NMM | NMM | 1 | 9 | 0 | 35.0 | refractory | minimal | negative | negative | 1.6 | 314 |
| 6 | 68 | 5/3/01 | NMM | NMM | 1 | 10 | (1) | 57.9 | refractory | moderate | positive | positive | ND | 256 |
| 7 | 61 | 6/29/01 | NMM | NMM | 0 | 3 | 0 | 115.6 | PR | moderate | negative | negative | ND | ND |
| 8 | 55 | 7/25/01 | NMM | NMM | 3 | 3 | 0 | 5.1 | CR1 | minimal | ND | ND | ND | ND |
| 9 | 49 | 8/14/01 | NMM | NMM | 1 | 1 | 0 | 12.6 | refractory | minimal | negative | positive | ND | 224 |
| 10 | 44 | 9/19/01 | NMM | NMM | 0 | 6 | 1 | 31.1 | refractory | large | positive | NA | ND | ND |
| 11 | 53 | 3/6/02 | NMM | NMM | 0 | 7 | 1 | 91.3 | CR5 | minimal | ND | ND | ND | ND |
| 12 | 67 | 4/10/02 | NMM | NMM | 5 | 4 | 0 | 56.1 | refractory | large | negative | negative | 3.1 | 176 |
| 13 | 49 | 6/21/02 | NMM | NMM | 2 | 2 | 0 | 10.8 | untested relapse | minimal | positive | positive | ND | 219 |
| 14 | 63 | 9/6/02 | NMM | NMM | 1 | 2 | 0 | 36.9 | CR2: MRD | minimal | negative | positive | 1.9 | 137 |
| 15 | 53 | 1/30/03 | NMM | NMM | 0 | 1 | (1) | 8.0 | CR1 | minimal | negative | negative | 1.8 | 223 |
| 16 | 58 | 2/11/03 | NMM | NMM | 0 | 4 | 1 | 63.8 | CR2 | minimal | negative | negative | 1.4 | 172 |
| 17 | 43 | 2/5/00 | NMM | NMM | 0 | 4 | 1 | 64.1 | refractory | minimal | positive | negative | ND | ND |
| 18 | 47 | 3/3/00 | NMM | NMM | 0 | 3 | 1 | 45.7 | untested relapse | minimal | negative | negative | 1.3 | 123 |
| 19 | 62 | 6/7/00 | NMM | NMM | 0 | 8 | 0 | 41.8 | PR | moderate | negative | positive | ND | |
| 20 | 70 | 10/6/00 | NMM | NMM | 1 | 8 | 1 | 34.2 | refractory | large | negative | negative | ND | 357 |
| 21 | 64 | 11/15/00 | NMM | NMM | 0 | 3 | 0 | 17.5 | refractory | large | positive | ND | ND | 125 |
| 22 | 58 | 12/8/00 | B: 3508 vs 3501 | NMM | 1 | 8 | 0 | 34.7 | CR2 | minimal | negative | negative | ND | 150 |
| 23 | 54 | 6/7/01 | A 02 mm | NMM | 0 | 7 | 1 | 76.3 | CR3 | minimal | negative | negative | 2.3 | 158 |
| 24 | 61 | 5/18/02 | NMM | NMM | 0 | 7 | 1 | 60.8 | refractory | large | negative | negative | 1.1 | 189 |
| 25 | 51 | 6/20/02 | NMM | NMM | 1 | 5 | 1 | 58.6 | CR2 | minimal | negative | negative | 3.7 | 140 |
| 26 | 66 | 1/28/03 | NMM | NMM | 0 | 5 | 1 | 34.7 | CR2 | minimal | negative | negative | 2.1 | 153 |
| 27 | 48 | 1/30/03 | NMM | NMM | 2 | 3 | 1 | 28.0 | CR2 | minimal | negative | negative | 2.2 | 165 |
| 28 | 48 | 5/17/03 | NMM | NMM | 0 | 3 | 0 | 32.1 | refractory | moderate | negative | ND | 4.1 | 167 |
| 29 | 57 | 5/20/03 | NMM | NMM | 0 | 2 | 0 | 10.5 | CR1§ | minimal | negative | negative | 2.4 | 225 |
| 30 | 50 | 5/29/03 | NMM | NMM | 0 | 1 | 91.3 | refractory | moderate | positive | positive | 1.4 | 169 | |
| 31 | 56 | 7/8/03 | A: 0301 vs 0302 | C: 0602 vs 0401/09N | ND | 5 | 0 | 10.0 | refractory | moderate | negative | positive | ND | 770 |
| 32 | 33 | 7/31/03 | NMM | C: 0303 vs 0401 | 0 | 6 | 1 | 87.6 | PR | minimal | negative | negative | 1.4 | 234 |
| 33 | 52 | 8/29/03 | NMM | NMM | 0 | 6 | 0 | 12.1 | PR | large | positive | positive | 3.0 | 162 |
Patient no.* . | Patient age, y . | HCT date . | Allele mismatch . | Antigen mismatch . | CCI score . | No. of prior regimens . | Autologous HCT failed (planned) . | Months from diagnosis to HCT . | Disease status at HCT† . | Disease burden‡ . | Marrow . | Flow cytometry . | Beta2 microglobulin, μg . | LDH . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 39 | 3/7/00 | NMM | NMM | 0 | 2 | 0 | 7.4 | CR1 | minimal | negative | negative | 1.5 | 187 |
| 2 | 52 | 4/29/00 | NMM | NMM | 0 | 2 | 0 | 12.1 | refractory | moderate | positive | negative | ND | ND |
| 3 | 52 | 5/2/00 | NMM | NMM | 0 | 2 | (1) | 4.6 | CR1 | minimal | negative | negative | 1.6 | 215 |
| 4 | 59 | 6/28/00 | NMM | NMM | 4 | 5 | 1 | 20.7 | PR | minimal | negative | negative | 5.6 | 255 |
| 5 | 39 | 11/17/00 | NMM | NMM | 1 | 9 | 0 | 35.0 | refractory | minimal | negative | negative | 1.6 | 314 |
| 6 | 68 | 5/3/01 | NMM | NMM | 1 | 10 | (1) | 57.9 | refractory | moderate | positive | positive | ND | 256 |
| 7 | 61 | 6/29/01 | NMM | NMM | 0 | 3 | 0 | 115.6 | PR | moderate | negative | negative | ND | ND |
| 8 | 55 | 7/25/01 | NMM | NMM | 3 | 3 | 0 | 5.1 | CR1 | minimal | ND | ND | ND | ND |
| 9 | 49 | 8/14/01 | NMM | NMM | 1 | 1 | 0 | 12.6 | refractory | minimal | negative | positive | ND | 224 |
| 10 | 44 | 9/19/01 | NMM | NMM | 0 | 6 | 1 | 31.1 | refractory | large | positive | NA | ND | ND |
| 11 | 53 | 3/6/02 | NMM | NMM | 0 | 7 | 1 | 91.3 | CR5 | minimal | ND | ND | ND | ND |
| 12 | 67 | 4/10/02 | NMM | NMM | 5 | 4 | 0 | 56.1 | refractory | large | negative | negative | 3.1 | 176 |
| 13 | 49 | 6/21/02 | NMM | NMM | 2 | 2 | 0 | 10.8 | untested relapse | minimal | positive | positive | ND | 219 |
| 14 | 63 | 9/6/02 | NMM | NMM | 1 | 2 | 0 | 36.9 | CR2: MRD | minimal | negative | positive | 1.9 | 137 |
| 15 | 53 | 1/30/03 | NMM | NMM | 0 | 1 | (1) | 8.0 | CR1 | minimal | negative | negative | 1.8 | 223 |
| 16 | 58 | 2/11/03 | NMM | NMM | 0 | 4 | 1 | 63.8 | CR2 | minimal | negative | negative | 1.4 | 172 |
| 17 | 43 | 2/5/00 | NMM | NMM | 0 | 4 | 1 | 64.1 | refractory | minimal | positive | negative | ND | ND |
| 18 | 47 | 3/3/00 | NMM | NMM | 0 | 3 | 1 | 45.7 | untested relapse | minimal | negative | negative | 1.3 | 123 |
| 19 | 62 | 6/7/00 | NMM | NMM | 0 | 8 | 0 | 41.8 | PR | moderate | negative | positive | ND | |
| 20 | 70 | 10/6/00 | NMM | NMM | 1 | 8 | 1 | 34.2 | refractory | large | negative | negative | ND | 357 |
| 21 | 64 | 11/15/00 | NMM | NMM | 0 | 3 | 0 | 17.5 | refractory | large | positive | ND | ND | 125 |
| 22 | 58 | 12/8/00 | B: 3508 vs 3501 | NMM | 1 | 8 | 0 | 34.7 | CR2 | minimal | negative | negative | ND | 150 |
| 23 | 54 | 6/7/01 | A 02 mm | NMM | 0 | 7 | 1 | 76.3 | CR3 | minimal | negative | negative | 2.3 | 158 |
| 24 | 61 | 5/18/02 | NMM | NMM | 0 | 7 | 1 | 60.8 | refractory | large | negative | negative | 1.1 | 189 |
| 25 | 51 | 6/20/02 | NMM | NMM | 1 | 5 | 1 | 58.6 | CR2 | minimal | negative | negative | 3.7 | 140 |
| 26 | 66 | 1/28/03 | NMM | NMM | 0 | 5 | 1 | 34.7 | CR2 | minimal | negative | negative | 2.1 | 153 |
| 27 | 48 | 1/30/03 | NMM | NMM | 2 | 3 | 1 | 28.0 | CR2 | minimal | negative | negative | 2.2 | 165 |
| 28 | 48 | 5/17/03 | NMM | NMM | 0 | 3 | 0 | 32.1 | refractory | moderate | negative | ND | 4.1 | 167 |
| 29 | 57 | 5/20/03 | NMM | NMM | 0 | 2 | 0 | 10.5 | CR1§ | minimal | negative | negative | 2.4 | 225 |
| 30 | 50 | 5/29/03 | NMM | NMM | 0 | 1 | 91.3 | refractory | moderate | positive | positive | 1.4 | 169 | |
| 31 | 56 | 7/8/03 | A: 0301 vs 0302 | C: 0602 vs 0401/09N | ND | 5 | 0 | 10.0 | refractory | moderate | negative | positive | ND | 770 |
| 32 | 33 | 7/31/03 | NMM | C: 0303 vs 0401 | 0 | 6 | 1 | 87.6 | PR | minimal | negative | negative | 1.4 | 234 |
| 33 | 52 | 8/29/03 | NMM | NMM | 0 | 6 | 0 | 12.1 | PR | large | positive | positive | 3.0 | 162 |
HCT indicates hematopoietic cell transplantation; NMM, no mismatch; CCI, Charleston Comorbidity Index; chemo, chemotherapy; BM, bone marrow; flow, flow cytometry; LDH, lactate dehydrogenase; F, female; M, male; CR, complete remission; ND, not done; NA, not available.
Patients 1 through 16 received transplants from an HLA-matched related donor; patients 17 through 33 received transplants from an unrelated donor.
At the last staging before HCT relative to the last pre-HCT therapeutic intervention made. CR was defined as no detectable disease. PR was defined as 50% reduction relative to the last staging. Patients were considered “refractory” to salvage therapy if they did not have a PR or CR to the last therapy given. Patients not administered therapy after having previously documented responsive disease were considered to have “untested relapse.”
Disease burden: minimal: largest lymph node less than 1.5 cm; moderate: largest lymph node greater than or equal to 1.5 cm and less than 5 cm; large: lymph node greater than or equal to 5 cm.
Failed induction.